Fundraising FoxBioMedPartners — Full Portfolio
20 tracked investments · listed companies and verified rows first
Alentis is a biotech company developing therapies for chronic liver disease, fibrosis, and cancer based on the molecular biology of liver disease.
AI & Machine LearningBiotechHealthtechMedical DevicesBasel, CH
Thomas Baumert(Founder)inMark Pruzanski(Chief Executive Officer)inLuigi Manenti(Chief Medical Officer)inJon Freve(Chief Financial Officer)inBryan Yoon(General Counsel and Chief Administrative Officer)inAditya Venugopal(Chief Business Officer)in
Co-investorsAvego BioScience CapitalFrazier Life SciencesJeito CapitalLongitude CapitalNovo HoldingsOrbiMed+5 more
Azafaros is a clinical-stage biopharmaceutical company developing small-molecule therapies for severe rare genetic metabolic disorders, including GM1/GM2 gangliosidoses, Niemann-Pick type C disease, and other conditions.
BiotechDeep TechHealthtechMedical DevicesLeiden, NL
Hans Aerts(Professor)Hermen Overkleeft(Professor)Stan van Boeckel(Professor)
Co-investorsBioGeneration VenturesForbionJeito CapitalPictet GroupAsahi Kasei Corporate Venture CapitalSeroba Life Sciences
Tubulis develops antibody-drug conjugates (ADCs) for cancer treatment, using proprietary conjugation platform technologies to create tumor-targeting therapeutics.
BiotechDeep TechMedical DevicesPlanegg-Martinsried, DE
Dominik Schumacher(Co-founder & CEO)inJonas Helma-Smets(Co-founder & Chief Scientific Officer)Christian Hackenberger(Scientific Co-founder)
Co-investorsAndera PartnersEQT Life SciencesNexTech VenturesAscenta CapitalBayern Kapitalcoparion+8 more
Antibiotic developer, maker of cefepime/enmetazobactam (EXBLIFEP).
Co-investorsAndera PartnersDelos CapitalEMBL VenturesXeraya CapitalForbion
Clinical-stage biopharmaceutical company developing RNA therapeutics for cardiac disease.
Co-investorscoparionHadean VenturesInkefEQT Life SciencesFund+Sunstone Capital
Immunos Therapeutics develops therapies for immuno-oncology and inflammatory diseases.
BiotechHealthtechMedical Devices
Co-investorsBackbone VenturesGimvLightspeed Venture PartnersMission BiocapitalPfizer Venture InvestmentsPfizer Ventures+1 more
Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.
BiotechHealthtechMedical Devices
Ilise Lombardo(Chief Executive Officer)inVolker Knappertz(Executive Vice President of Research & Development)inMichael Samar(Chief Financial Officer)inRob Lasser(Chief Medical Officer)in
Co-investorsJeito CapitalRoche Venture FundSofinnova PartnersEQTEQT Life SciencesForbion+2 more
Immunotherapies for T cell-mediated autoimmune conditions via modulation of coronin 1; spin-off from the University of Basel.
Rajesh Jayachandran, MD PhD(Founder)in
Co-investorsKickfundVenture Kick
Scenic Biotech develops modifier therapy, a genetic medicine approach that targets secondary functions in the genome to neutralize the impact of disease-causing mutations.
AI & Machine LearningBiotechDeep TechDigital HealthHealthtech
Co-investorsBioGeneration VenturesEIR VenturesInkefOxford Science Enterprises
T-CURX is a venture-backed biotechnology company developing autologous CAR-T cell therapies using proprietary non-viral technologies, including in vivo and bedside-manufactured CAR-T approaches based on T cell-targeted LNP delivery of Sleeping Beauty transposon vectors.
BiotechHealthtechWürzburg, DE
Michael Hudecek(Co-founder)Christoph Rader(Co-founder & Member of the Scientific Advisory Board)Ulf Grawunder(Co-founder & CEO)in
Co-investorsHighlight Capitali&i Biotech FundBayern Kapital
TOLREMO therapeutics develops small molecule inhibitors targeting transcriptional resistance mechanisms in cancer, with a lead clinical candidate TT125-802 designed for solid tumors and hematological malignancies as both monotherapy and combination treatment.
Biotech
Co-investorsredalpine
Topas Therapeutics develops nanoparticle-based therapies to induce immune tolerance for autoimmune and immune-mediated diseases.
BiotechHealthtech
Hugo Fry(Chief Executive Officer)inChristian Schröter(Chief Operating Officer)Cristina de Min(Chief Medical Officer)Anne Burger(Chief Financial Officer)Alex Marshall(Chief Business Officer)in
Co-investorsEMBL VenturesGimvBoehringer Ingelheim Venture FundEpidarex Capital
TRiCares develops the Topaz Transfemoral Tricuspid Heart Valve Replacement (TTVR) System, a minimally invasive device for treating tricuspid regurgitation.
BiotechHardwareHealthtechMedical DevicesFrance, FR
Ahmed Elmouelhi(President & CEO)inEsther Gerteis(Senior VP Medical & Regulatory Affairs)inMichael Litzenburger(VP R&D)in
Co-investorsEuropean Investment Bank415 CapitalAndera PartnersBayern KapitalCapDecisif ManagementKarista
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
AMAL Therapeutics SADimericon TherapeuticsiDEL Therapeutics GmbHOmnilinX Therapeutics AGPRECIRIX NVSalvina TherapeuticsTRiCares
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.